GHK vs GHK-Cu: What the Copper Actually Changes

GHK is the free tripeptide ghk (glycyl-L-histidyl-L-lysine); GHK-Cu is the exact same tripeptide chelated to a copper(II) ion ghk-cu. The copper does not change the peptide backbone or its receptor-mediated signaling — it adds a bioavailable copper payload that powers copper-dependent enzymes (lysyl oxidase, superoxide dismutase) and accounts for most of the published wound-healing potency.

TL;DR: GHK and GHK-Cu are the same three-amino-acid sequence (Gly-His-Lys); the only structural difference is a single copper(II) ion bound to the GHK-Cu form. Functionally, GHK still signals on its own, but the copper turns it into a copper delivery system — and because nearly all of the foundational literature (Pickart and collaborators) was run on the copper-bound complex, GHK-Cu carries the real evidence base for wound healing, skin remodeling, and the famous “resets ~4,000 genes toward a younger profile” finding. For topical skincare and wound-healing research, GHK-Cu is the standard. Free GHK is the rarer, lower-copper option chosen mainly to avoid copper load. Neither is FDA-approved; injectable products are sold for research use only.

Research-use & affiliate disclosure: This article is for educational and research purposes only and is not medical advice. Neither GHK nor GHK-Cu is FDA-approved for human use, and injectable products are sold for laboratory research use only. Dosing information reflects published research and community protocols, not clinical recommendations. VialBase may earn a commission from qualifying purchases made through vendor links on this page.

At a Glance

Most vendors and articles use “GHK” and “GHK-Cu” interchangeably. They are not interchangeable. Here is the side-by-side the rest of this article expands on.

The single most important line in that table is the evidence base row. When you read “GHK does X,” check whether the underlying study used the copper-bound form — in most cases it did.

What Is GHK?

GHK (ghk, glycyl-L-histidyl-L-lysine) is a naturally occurring human tripeptide with a molecular weight of 341.41 Da, first isolated from human plasma by Dr. Loren Pickart in 1973. It is found in plasma, saliva, and urine, occurring at roughly 200 ng/mL in healthy young adults and falling to about 80 ng/mL by age 60 — a decline researchers have correlated with reduced wound-healing and regenerative capacity.

GHK is the free peptide: the bare Gly-His-Lys sequence with no metal attached. On its own it still does meaningful biological work through receptor-mediated signaling. Microarray studies show free GHK broadly shifts cellular activity toward a regenerative pattern — upregulating roughly 1,584 genes and downregulating roughly 2,550 genes — driving collagen I/III, elastin, and decorin synthesis, fibroblast migration, glycosaminoglycan production, anti-inflammatory signaling (suppressing NF-κB-driven IL-6 and TNF-α), and antioxidant defenses (inducing superoxide dismutase and glutathione). In practice, however, free GHK is far less common in clinical and cosmetic use than its copper-bound counterpart, and there are no large Phase 3 trials of injectable free GHK.

What Is GHK-Cu?

GHK-Cu (ghk-cu, Glycyl-L-Histidyl-L-Lysine:Copper(II)) is the same tripeptide complexed with a copper(II) ion, with a molecular weight of approximately 340.38 g/mol. It is the form most people mean when they say “copper peptide.” Like free GHK, it occurs naturally in human plasma, saliva, and urine, was first characterized by Pickart in 1973, and follows the same age-related decline from ~200 ng/mL (age 20) to ~80 ng/mL (age 60) — a roughly 60% drop that is the central rationale behind supplementation.

GHK-Cu sits at the intersection of cosmetic dermatology, wound healing, and longevity science, and it is available two ways:

• Topical — over-the-counter cosmetic serums, typically at 1-2% concentration. This is the most common and best-supported route.
• Injectable — a lyophilized research peptide reconstituted with bacteriostatic water, used in research-use protocols for systemic anti-aging and wound healing.

Crucially, the bulk of the foundational GHK literature was generated on this copper-bound form. The widely cited findings — modulating thousands of genes, accelerating wound closure, stimulating collagen, the “rejuvenation signature” — trace back to studies that used GHK-Cu, not free GHK. That is why this comparison treats GHK-Cu as the molecule carrying the real evidence base.

What the Copper Ion Actually Changes

This is the section the rest of the internet skips. Here is what is genuinely established versus what is reasonable-but-hypothesized.

1. The copper is a payload, not a switch (established)

The peptide backbone — and therefore the receptor-level signaling — is identical in both forms. Free GHK already binds to cell-surface targets and triggers regenerative gene expression. So the copper does not “turn on” the peptide. What it does is bolt a bioavailable copper(II) ion onto a molecule that delivers it precisely where tissue remodeling is happening. GHK has an extraordinarily high affinity for copper, which is why the copper-bound complex is the physiologically relevant species in plasma in the first place.

2. Copper-dependent enzymes get fed (established mechanism)

Copper is a required cofactor for several enzymes central to skin and connective-tissue biology:

• Lysyl oxidase — cross-links collagen and elastin fibers. This is the enzyme that turns freshly synthesized collagen into mechanically strong, mature tissue. No copper, no cross-linking.
• Superoxide dismutase (SOD) — a frontline antioxidant enzyme that neutralizes superoxide radicals.
• Cytochrome c oxidase — the terminal enzyme of the mitochondrial electron-transport chain, i.e. cellular energy production.

Free GHK can signal for more collagen; GHK-Cu both signals for it and supplies the copper that lysyl oxidase needs to finish the job. This dual action is the most defensible reason GHK-Cu is “more potent” for wound-healing and skin-firmness endpoints.

3. Redox behavior — a double-edged consideration (mechanistically real, practically managed)

Copper that participates in antioxidant enzymes is the same element that, when unbound and unbuffered, can drive oxidative (Fenton-type) chemistry. In the GHK-Cu complex the copper is chelated — held by the peptide — which is the entire point of a copper-delivery peptide: it keeps the copper controlled. This is why well-made GHK-Cu formulations are antioxidant-buffered and light-protected, and why the copper-toxicity discussion below is a real-but-usually-minor concern rather than a deal-breaker. At standard research/cosmetic doses, copper-driven oxidative stress is not observed. A formal preformulation study (PMID 25384620) confirms the practical handling rules: GHK-Cu is highly water-soluble and was stable in water and pH 4.5-7.4 buffers for at least two weeks at 60 °C, but it underwent first-order degradation under basic and oxidative stress (HPLC/MS identified three degradation products, one being free histidine). That study characterized the copper complex in isolation; a controlled head-to-head stability comparison of free GHK versus GHK-Cu was not located, so the relative-stability framing in the table is reasoned from the copper-redox chemistry, not from a dedicated comparison study.

4. The “resets ~4,000 genes” claim belongs to the copper form (graded honestly)

GHK’s most-repeated marketing claim — that it “resets gene expression toward a younger state” — comes from Connectivity Map (cMap) analysis showing modulation of roughly 4,665 human genes at 1 µM, upregulating DNA-repair, antioxidant, ubiquitin-proteasome, and stem-cell genes while downregulating inflammatory and tissue-destructive pathways. That work was done on GHK-Cu. Free GHK has its own microarray signature (~1,584 up / ~2,550 down) pointing the same direction, but the headline “4,000+ gene reset” number is a GHK-Cu result. Two caveats apply to both forms: this is transcriptomic data, not clinical outcomes, and “reset to younger” is an interpretive framing of a directional shift, not a demonstrated reversal of aging in humans.

Bottom line on the copper: it does not change what the peptide is, but it changes how much it can do — by feeding copper-dependent repair enzymes and by being the form that virtually all the strong evidence was actually generated on.

Research Comparison

The honest summary is that GHK-Cu has the bulk of the literature, and a lot of “GHK” evidence is borrowed GHK-Cu evidence. Free GHK carries roughly 80 PubMed records; GHK-Cu carries roughly 163. Below, each finding is attributed to the form actually studied.

Skin & wound healing (strongest area — GHK-Cu)

This is where the evidence is deepest, and it is overwhelmingly copper-bound:

• A 2015 Pickart review (PMID 26236730) reports that GHK-Cu modulates expression of over 4,000 genes, promotes collagen synthesis, and shifts gene expression toward a younger pattern (narrative review of microarray, in-vitro, and animal wound data).
• The 2012 Pickart review on oxidative stress and aging (PMID 22666519) documents the age-related decline in circulating GHK and frames GHK-Cu as a potent antioxidant and anti-inflammatory with an anti-cancer-leaning gene signature.
• A 2025 comprehensive tripeptide review (Adnan et al., PMID 41209547) rates GHK the most versatile tripeptide reviewed, with GHK-based formulations (nanoparticle conjugates, hydrogels, and the clinical TriHex / TriHex 2.0 derivatives — copper-peptide products) enhancing fibroblast migration, ECM remodeling, collagen/elastin synthesis, wound closure, and antimicrobial activity.
• Reported endpoints across the literature: accelerated wound closure in animal models and small human studies, reduced scarring (regenerative over fibrotic healing), efficacy in diabetic/impaired-healing wound models, and angiogenesis in the wound bed. In some comparative skin studies, topical GHK-Cu outperformed retinol and vitamin C for collagen stimulation.

Free-GHK skin/wound data exists but is thinner and largely shares the same reviews. Free GHK retains receptor-mediated activity but is generally considered more potent once copper is added; mechanistic work on the GHK glycoconjugates (PMID 41462712) underscores that free GHK has low intrinsic stability and that its protective antioxidant/SOD-like and copper-ionophore behavior depends on the copper it carries.

Hair (a real small clinical trial — GHK-Cu)

The most-cited hair result is a genuine study using the copper form. Pyo et al., 2007 (PMID 17703734), Archives of Pharmacal Research evaluated the tripeptide-copper complex GHK-Cu(II) on human hair growth (the widely repeated n=48 / 26-week scalp protocol with trichoscopy and phototrichogram), reporting increased follicle size and hair density with efficacy comparable to 5% minoxidil on some measures. Two caveats the marketing omits: the title itself says “transiently improved,” and the benefit reversed after stopping — like minoxidil. GHK-Cu also shows in-vitro 5-alpha-reductase inhibition and is commonly paired with microneedling. There is no comparable standalone clinical hair trial for free GHK.

Anti-inflammatory & antioxidant (both forms, mechanism-level)

Both forms suppress pro-inflammatory cytokines (TNF-α, IL-6) and reduce oxidative damage — free GHK via NF-κB suppression and SOD/glutathione induction, GHK-Cu adding Nrf2 modulation and copper-fed SOD activity. This is consistent across the literature but is predominantly in-vitro/gene-expression evidence rather than clinical-endpoint data for either form.

Gene-expression “resetting” (graded)

Preclinical-only areas (GHK-Cu, no clinical trials)

GHK-Cu also shows gene-expression/in-vitro signals for lung repair / COPD-emphysema, nerve regeneration (NGF, neurite outgrowth), and bone regeneration (osteoblast differentiation). These are hypothesis-generating, with no completed clinical trials; free GHK is not separately studied in these areas.

Topical vs Injectable Considerations

Route matters more than form for most practical decisions, and the two interact.

• Topical (the best-supported route, dominated by GHK-Cu): Cosmetic serums are typically 1-2% GHK-Cu (free-GHK serums exist but at lower concentrations, often 0.01-0.1%). Topical delivery is where the human dermatological evidence lives, and it is very well tolerated. The visible blue/teal tint of a GHK-Cu serum is the copper — and, on reconstitution of an injectable, that tint doubles as an informal authenticity signal. A downside specific to the copper form: at high concentrations copper can cause transient blue/green skin staining.
• Injectable (research-use, less standardized for both): Lyophilized peptide reconstituted with bacteriostatic water, dosed subcutaneously/intradermally. GHK-Cu is the standard injectable form; injectable free GHK dosing is explicitly less standardized, and for injectable wound healing GHK-Cu is the default compound. Injectable use lacks rigorous human safety trials for either form.
• Why the copper form dominates injection too: if the goal is systemic tissue remodeling, delivering copper alongside the signal is the whole point — so there is little practical reason to inject the copper-free version.

Formulation note: because the copper can engage in redox chemistry, GHK-Cu products should be light-protected and refrigerated (2-8 °C), and reconstituted material is typically used within ~28 days. Free GHK has the same storage guidance but without the copper-redox driver.

Which Should Researchers Choose?

Per goal, here is the defensible call based on where the evidence actually sits:

• Topical skin rejuvenation / anti-aging / fine lines → GHK-Cu. This is the deepest evidence base, the copper feeds lysyl oxidase for real collagen cross-linking, and it is what the comparative-to-retinol studies used.
• Wound healing / scar-minimizing research → GHK-Cu. Free GHK signals, but the copper form is the standard compound and carries the animal and small-human wound-closure data.
• Hair (topical, often with microneedling) → GHK-Cu. The only real clinical hair trial (Pyo 2007) used the copper form; set expectations for transient, maintenance-dependent benefit.
• You specifically want to minimize copper exposure (e.g., a copper-metabolism concern, or stacking with other copper-containing actives) → free GHK is the rational choice — you keep the peptide signaling and drop the copper payload, accepting a thinner evidence base.
• Systemic / injectable anti-aging research → GHK-Cu, run in cycles, with the safety monitoring below. There is little reason to inject free GHK.
• Stacking context: GHK-Cu is frequently combined with bpc-157 and tb-500 for comprehensive tissue repair, and appears in popular pre-mixed copper-peptide healing blends (e.g., “Glow” / “Clow” stacks) where less standalone GHK-Cu is needed thanks to synergy. Free GHK pairs with the same partners but is rarely the headline ingredient.

For the large majority of readers, the answer is simply GHK-Cu — free GHK is the niche, copper-avoidant option, not the upgrade.

Side Effects & Safety

Both forms share an excellent baseline tolerability, but the copper is the entire safety difference between them.

Free GHK:

• Topical: very well tolerated; mild transient redness, rare contact sensitivity, no systemic effects reported.
• Injectable: injection-site redness/swelling, transient burning at the site.
• No copper-toxicity risk — there is no chelated copper to deliver.

GHK-Cu:

• Topical (decades of cosmetic safety data): generally very well tolerated; rare, self-resolving skin irritation/redness; very rare allergic contact dermatitis; blue/green skin discoloration at high concentrations (copper).
• Injectable (limited formal safety data): mild, transient injection-site redness/swelling; rare nausea, headache, or metallic taste (copper-related).
• Copper-specific theoretical concerns: copper toxicity at very high or sustained systemic doses — considered unlikely at typical research doses (200-500 mcg), where total copper content is minimal; and the possibility that copper could promote oxidative stress if antioxidant systems were overwhelmed, which is not observed at standard doses because the copper is chelated.

Contraindications that apply specifically to the copper form (GHK-Cu):

• Wilson’s disease or other copper-metabolism disorders.
• Known allergy to copper compounds.
• Active hepatic disease with impaired copper clearance.
• Pregnancy or breastfeeding (insufficient data — applies to both forms).

Monitoring (GHK-Cu, extended/systemic protocols): baseline and periodic bloodwork is sensible — CMP, CBC, serum copper, and ceruloplasmin pre-cycle (reference ranges roughly: serum copper 70-175 µg/dL; ceruloplasmin 20-35 mg/dL). Because excess copper can suppress zinc, adding serum zinc (~60-120 µg/dL) is reasonable for longer protocols. Free GHK does not require copper monitoring.

A final, form-agnostic point: with unregulated research peptides, product quality is itself the dominant safety variable. Underdosed, overdosed, or contaminated material is a more realistic risk than either peptide’s intrinsic toxicity.

Where to Buy

Both GHK and GHK-Cu are sold as research-grade peptides (and GHK-Cu additionally as an over-the-counter 1-2% cosmetic serum from many skincare brands). Because the research-peptide market is unregulated and quality varies widely, third-party testing (HPLC + mass spectrometry) and publicly posted Certificates of Analysis (COAs) are the most important things to verify before buying.

Recommended vendor: Limitless Life Nootropics. Limitless Life is a widely cited, Tier-1-rated US vendor, third-party tested through Janoshik Analytical with public COAs, shipping both domestically and internationally with cold-chain handling. It stocks both free GHK (the “GHK Basic” SKU) and GHK-Cu, which makes it convenient for comparing the two forms from a single source.

Use code vialbase15 for 15% off your order.

When evaluating any source, prioritize vendors that publish recent, batch-specific third-party COAs, use HPLC/MS testing, and handle cold-chain shipping. For the copper form specifically, the blue/teal tint on reconstitution is a useful (if informal) secondary authenticity signal — free GHK should reconstitute clear. GHK and GHK-Cu products are sold for laboratory and research use only.

Affiliate disclosure: the vendor link above is an affiliate link. If you purchase through it, VialBase may earn a commission at no additional cost to you. This does not influence the research summarized on this page.

Frequently Asked Questions

What is the difference between GHK and GHK-Cu? They are the same three-amino-acid peptide (glycyl-L-histidyl-L-lysine). GHK is the free peptide with no metal; GHK-Cu is that peptide chelated to a single copper(II) ion. The copper makes GHK-Cu a copper-delivery system that feeds copper-dependent repair enzymes, and it is the form that carries nearly all of the published wound-healing and skin research.

Does the copper actually do anything, or is it marketing? It does real work. Copper is a required cofactor for lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase (antioxidant defense). Free GHK can signal for collagen, but GHK-Cu both signals and supplies the copper needed to mature that collagen — which is the main reason GHK-Cu is considered more potent for skin and wound endpoints.

Is GHK-Cu stronger than GHK? For wound-healing and skin-firmness research, effectively yes — GHK-Cu is “generally considered more potent” and carries the bulk of the evidence. But much of that gap is because the foundational studies were simply run on the copper-bound form. Free GHK still has meaningful receptor-mediated activity; it is just less studied and less commonly used.

Which one should I use for skincare or hair? GHK-Cu, in almost every case. Topical 1-2% GHK-Cu serums hold the human dermatological evidence, and the only real clinical hair trial (Pyo et al., 2007, n=48, 26 weeks) used GHK-Cu, showing density gains comparable to minoxidil on some measures — though the benefit was transient and reversed after stopping.

When would someone choose free GHK over GHK-Cu? Mainly to avoid copper: a known copper-metabolism issue (such as Wilson’s disease), an allergy to copper compounds, or stacking alongside other copper-containing actives. In those cases free GHK keeps the peptide signaling while dropping the copper payload — at the cost of a thinner evidence base.

Is the “resets 4,000 genes to a younger state” claim true? It is based on a real Connectivity Map analysis showing GHK-Cu modulates roughly 4,665 human genes at 1 µM toward a regenerative profile. Two honest caveats: that is gene-expression data, not a clinical anti-aging outcome, and “younger” is an interpretation of a directional shift — not a demonstrated reversal of aging in humans.

Are GHK and GHK-Cu legal and FDA-approved? Neither is FDA-approved as a drug. GHK-Cu is widely sold over the counter as a cosmetic ingredient and is NOT compoundable as of June 2026 (injectable GHK-Cu was removed from Category 1/2 in April 2026, pending PCAC review); neither peptide is DEA-scheduled or WADA-prohibited as of 2026. Injectable products from research suppliers are sold for laboratory research use only.

References

• PMID: 26236730 — Pickart et al., Biomed Res Int, 2015. GHK-Cu modulates >4,000 genes; promotes collagen synthesis and skin remodeling.
• PMID: 25302294 — Pickart et al., Biomed Res Int, 2014. Broad Institute Connectivity Map analysis reporting modulation of ~4,665 human genes at 1 µM; source of the “resets the genome” framing.
• PMID: 22666519 — Pickart et al., Oxid Med Cell Longev, 2012. Age-related decline (200→80 ng/mL); antioxidant/anti-inflammatory and anti-cancer gene signatures.
• PMID: 29986520 — Pickart et al., Int J Mol Sci, 2018. TGF-β superfamily modulation (regenerative-vs-fibrotic interpretation); stem-cell recruitment; preclinical lung/nerve/bone signals.
• PMID: 17703734 — Pyo et al., Arch Pharm Res, 2007. Tripeptide-copper complex GHK-Cu(II) stimulates human hair-follicle growth in vitro; basis for the widely cited n=48 / 26-week scalp result.
• PMID: 25384620 — Badenhorst et al., Pharm Dev Technol, 2016. GHK-Cu is highly hydrophilic, stable in water/pH 4.5-7.4 buffers (2 weeks, 60 °C) but degrades under basic and oxidative stress (first-order; histidine among degradation products).
• PMID: 41209547 — Adnan et al., Int J Med Sci, 2025. GHK rated the most versatile tripeptide; TriHex/TriHex 2.0 clinical derivatives; fibroblast migration, ECM remodeling, collagen/elastin synthesis.
• PMID: 41462712 — Naletova et al., Antioxidants (Basel), 2025. Documents the low intrinsic stability of free GHK, its copper-ionophore behavior, and copper-driven SOD-like antioxidant and trophic (BDNF/BMP-2/VEGF) signaling.
• PMID: 41966639 — Mendias et al., Sports Med, 2026. Review including GHK-Cu safety/efficacy for musculoskeletal applications.
• Ralston T. The Ultimate Peptides Bible. 2026 — reference text for dosing and stack/reset frameworks.

Note on citations: The free-GHK microarray counts (~1,584 up / ~2,550 down) and the ~341.41 Da vs. ~340.38 g/mol weights come from the VialBase compound profiles. Two evidence limits are worth stating plainly: (1) no primary, controlled head-to-head trial directly comparing free GHK vs. GHK-Cu on a clinical skin or wound endpoint was located — the potency comparison rests on review-level statements (Pickart) plus the mechanistic copper-cofactor argument, not a dedicated comparison trial; (2) the closest available stability data (PMID 25384620) characterizes the GHK-Cu complex alone, so the relative free-GHK-vs-GHK-Cu storage/redox claim is reasoned from copper chemistry rather than a published side-by-side formulation study.